Chinese oncology drug developer Tot Biopharm raises $75.2m in HK IPO

Chinese oncology drug developer Tot Biopharm raises $75.2m in HK IPO

Photo by Louis Reed on Unsplash

Tot Biopharm, a Chinese clinical-stage biopharma firm specialized in innovative oncology drugs and therapies, has raised about $75.2 million in an initial public offering (IPO) on the main board of the Hong Kong stock exchange on Friday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter